No Data
No Data
Founder Securities: "Refining Going Global + Expanding Product Categories" is the next five-year important incremental opportunity for China's CXOs.
In addition to the USA market, diversified production capacity layout, establishing new strategic market cooperative relationships, expanding the forefront new emerging pharmaceutical field, and trying new mutually empowering strategic cooperative business models are important measures for the growth path of China's CXO in the next five years.
Trending Industry Today: FRONTAGE Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
July 11th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(LIST1261.HK)$ is trending higher today with 8 constituents up, 1 constituents down and FRONTAGE
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stocks are fluctuating. Biomedical stocks have all fallen back due to the policy of innovative drug bullishness. Institutions say that negotiating difficulty has increased in the new environment.
Biomedical stocks fell across the board. As of press time, Remegen (09995) fell 20.18% to HKD 17.24, Tigermed (03347) fell 6.59% to HKD 26.95, Wuxi AppTec (02359) fell 3.95% to HKD 27.95, and Junshi Bio (01877) fell 2.25% to HKD 12.18.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Yao Ming Kangde (02359) will cancel 31,500 stock options
Wuxi Apptec (02359) announced that the stock options of the 2019 A-share incentive plan were granted for the first time after adjustment...
No Data